InnoCan Pharma's book value per share for the quarter that ended in Mar. 2026 was €1.00.
During the past 12 months, InnoCan Pharma's average Book Value Per Share Growth Rate was 5.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of InnoCan Pharma was 240.20% per year. The lowest was -18.40% per year. And the median was 15.10% per year.
InnoCan Pharma's current price is €1.745. Its book value per share for the quarter that ended in Mar. 2026 was €1.00. Hence, today's PB Ratio of InnoCan Pharma is 1.75.
During the past 8 years, the highest P/B Ratio of InnoCan Pharma was 138.51. The lowest was 1.62. And the median was 10.68.
InnoCan Pharma (HAM:IP40) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
InnoCan Pharma Book Value per Share Related Terms
InnoCan Pharma Book Value per Share Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Book Value per Share Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma PB Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (HAM:IP40) has a Book Value per Share of €1.00 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Book Value per Share too high?
InnoCan Pharma's current Book Value per Share is €1.00. Overall, InnoCan Pharma has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Book Value per Share compare to PG and CL?
InnoCan Pharma's Book Value per Share of €1.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Consumer Packaged Goods company?
A good Book Value per Share depends on the Consumer Packaged Goods industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Book Value per Share is €1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.83, compared to a current price of €1.75 — trading 77.7% below its estimated fair value. The current Book Value per Share is €1.00. InnoCan Pharma's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Book Value per Share is €1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.75 is trading 77.7% below its estimated GF Value™ of €7.83.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Book Value per Share: €1.00
GF Value™: €7.83 vs. price of €1.75 (77.7% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
64GF Score
Get the complete analysis for HAM:IP40
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
